Drug – bio-affecting and body treating compositions – Solid synthetic organic polymer as designated organic active... – Aftertreated polymer
Reexamination Certificate
2001-07-27
2004-02-10
Page, Thurman K. (Department: 1675)
Drug, bio-affecting and body treating compositions
Solid synthetic organic polymer as designated organic active...
Aftertreated polymer
C424S078010, C424S078190, C424S078370
Reexamination Certificate
active
06689350
ABSTRACT:
BACKGROUND OF THE INVENTION
Polyesters are used routinely by those skilled in the art in various drug delivery systems.
For example, U.S. Pat. No. 5,942,252 describes a microcapsule comprising as its biocompatible excipient a poly(lactide-co-glycolide), poly(lactide), poly(glycolide), copolyoxalate, polycaprolactone, poly(lactide-co-caprolactone), poly(esteramide), polyorthoester, poly(p-hydroxybutyric) acid and/or polyanhydride for use in delivering antigens or vaccines into and through mucosally-associated lymphoid tissue.
WO 99/29885 describes a process for degrading poly(ester-amides) and poly(ester-urethanes) encapsulating chemicals, drugs, enzymes, microorganisms and seeds by introducing the polymer to an aqueous nutrient solution and inoculating the solution with a culture containing a selected bacteria.
WO 98/36013 describes aliphatic-aromatic dihydroxy compounds for use as controlled drug delivery systems.
WO 97/39738 describes preparation of microparticles of a sustained release ionic conjugate comprising a free carboxyl group containing biodegradable polymers and a free amino group-containing drug.
SUMMARY OF THE INVENTION
Polyesters, polythioesters, and polyamides which degrade into useful biologically active compounds have now been developed. Accordingly, the invention provides a polymer of the invention which is polymer comprising a backbone, wherein the backbone comprises ester, thioester, or amide linkages, and wherein the backbone comprises one or more groups that will yield a biologically active compound upon hydrolysis of the polymer.
The invention also provides a pharmaceutical composition comprising a polymer of the invention and a pharmaceutically acceptable carrier.
The invention also provides a therapeutic method for treating a disease in an animal comprising administering to an animal in need of such therapy, an effective amount of a polymer of the invention.
The invention also provides a method of delivering a biologically active compound to a host comprising administering to the host a biocompatible and biodegradable polymer of the invention, which degrades into the biologically active compound.
The invention provides a polymer of the invention for use in medical therapy, as well as the use of a polymer of the invention for the manufacture of a medicament useful for the treatment of a disease in a mammal, such as a human.
The invention also provides processes and intermediates disclosed herein that are useful for preparing a polymer of the invention.
REFERENCES:
patent: 4062855 (1977-12-01), Allan et al.
patent: 4126445 (1978-11-01), Allan et al.
patent: 4684620 (1987-08-01), Hruby et al.
patent: 4757128 (1988-07-01), Domb et al.
patent: 4792598 (1988-12-01), Ziegast
patent: 4857311 (1989-08-01), Domb et al.
patent: 4868274 (1989-09-01), Gupta et al.
patent: 4886870 (1989-12-01), D'Amore et al.
patent: 4888176 (1989-12-01), Langer et al.
patent: 4891225 (1990-01-01), Langer et al.
patent: 4906474 (1990-03-01), Langer et al.
patent: 4997904 (1991-03-01), Domb
patent: 4999417 (1991-03-01), Domb
patent: 5082925 (1992-01-01), Shalaby et al.
patent: 5175235 (1992-12-01), Domb et al.
patent: 5259968 (1993-11-01), Emert et al.
patent: 5264540 (1993-11-01), Cooper et al.
patent: 5498729 (1996-03-01), Domb
patent: 5514764 (1996-05-01), Frecthet et al.
patent: 5518730 (1996-05-01), Fuisz
patent: 5545409 (1996-08-01), Laurencin et al.
patent: 5629009 (1997-05-01), Laurencin et al.
patent: 5902599 (1999-05-01), Anseth et al.
patent: 6071530 (2000-06-01), Polson et al.
patent: 6153212 (2000-11-01), Mao et al.
patent: 288311 (1991-03-01), None
patent: 288387 (1991-03-01), None
patent: 0246341 (1987-11-01), None
patent: 9000237 (1991-08-01), None
patent: WO-91/09831 (1991-07-01), None
patent: WO-97/39738 (1997-10-01), None
patent: WO-98/36013 (1998-08-01), None
patent: WO-99/12990 (1999-03-01), None
patent: WO-99/29885 (1999-06-01), None
patent: WO-01/28492 (2001-04-01), None
patent: WO-02/09767 (2002-02-01), None
patent: WO-02/09768 (2002-02-01), None
patent: WO-02/09769 (2002-02-01), None
Erdmann et al. (“Chapter 5: Polymeric Prodrugs: Novel Polymers with Bioactive Components”, In: Tailored Polymeric Materials for Controlled Delivery Systems, I. McCullough, et al., (Editors), ACS Symposium Series 709, ACS: Washington, D.C., (1998), pp. 83-91, Provided by Applicant as IDS.*
Anastasiou, T.,et al. ,“Synthesis of Novel , Degradable Polyanhydrides Containing Para-Aminosalicylic Acid as Drug Delivery Devices for Tuberculosis Treatment”,Polymer Preprints, 41(2), (2000), pg. 1366.
Chatterjee, R.,et al. ,“Mechanism for the Increase in Solubility of Deoxyhemoglobin S Due to Cross-Linking the beta Chains between Lysine-82beta1 and Lysine-82beta2”,Biochemistry, 21, (1982),5901-5909.
Davaran, S.,et al. ,“Release of 5-amino Salicylic Acid from Acrylic Type Polymeric Prodrugs Designed for Colon-specific Drug Delivery”,Journal of Controlled Release, 58, (1999),279-287.
Erdmann, L.,et al. ,“Polymer Prodrugs with Pharmaceutically Active Degradation Products”,Proceedings of the 1997 American Chemical Society Las Vegas Meeting, Las Vegas, NV,(Sep. 7-12, 1997),p. 570-571.
Erdmann, L.,et al. ,“Polymeric Prodrugs: Novel Polymers with Bioactive Components”,American Chemical Society, (1993),pp. 83-91.
Jiang, H.L. , et al. ,“Synthesis, Characterization and In Vitro Degradation of a New Family of Alternate Poly(ester-anhydrides) Based on Aliphatic and Aromatic Diacids”,Biomaterials, 22, (2001),211-218.
Langer, R.,“New Methods of Drug Delivery”,Science, 249, (Sep. 1990), 1527-1533.
Schacht, E.,et al. ,“Polymers for Colon Specific Drug Delivery”,Journal of Controlled Release, 39, (1996),327-338.
Anastasiou, T.J., “Novel Polyanhydrides with Enhanced Thermal and Solubility Properties”,Macromolecules, 33(17), (2000), pp. 6217-6221.
Anastasiou, T.J., “Novel, Degradable Polyanhydrides”,25th Annual Meeting Transactions of the Society for Biomaterials, Abstract, (1999), p. 79.
Anastasiou, T.J., “Synthesis of Novel, Degradable Polyanhydrides Containing Para-Aminosalicylic Acid as Drug Delivery Devices for Tuberculosis Treatment”,Polymer Preprints, 41(2), (Aug. 2000) pp. 1366-1367.
Attawia, M.A., “Biocompatibility Testing of Poly(anhydride-co-imides) Containing Pyromellitylimidoalanine”,The 21st Annual Meeting of the Society for Biomaterials, Abstract,(1994), p. 222.
Attawia, M.A., “Cytotoxicity testing of poly(anhydride-co-imides) for orthopedic applications”,Journal of Biomedical Materials Research, 29, (1995),pp. 1233-1240.
Attawia, M.A., “In Vitro Bone Biocompatibility of Poly(anhydride-co-imides) Containing Pyromellitylimidoalanine”,Journal of Orthopedic Research, 14, (1996), pp. 445-454.
Attawia, M.A., “Proliferation, Morphology, and Protein Expression by Osteoblasts Cultured on Poly(anhydride-co-amides)”,J. Biomed. Mater. Res.(Appl. Biomater),48, (1999), pp. 322-327.
Attawia, M.A., “Regional drug delivery with radiation for the treatment of Ewing's sarcoma —In vitro development of a taxol release system”,Journal of Controlled Release, 71, (2001), pp. 193-202.
Attawia, M.A., “The long Term Osteoblast Response to Poly(anhydride-co-imides): A New Degradable Polymer for Use in Bone”,Proc. of the Fifth World Biomaterials Congress, Toronto, Canada, (1996), p. 113.
Beaton, M.L., “Synthesis of a novel poly(anhydride-ester)”,The Rutgers Scholar—An Electronic Bulletin of Undergraduate Research, 3, www.rutgersscholar.rutgers.edu/volume03/beatuhri/beatuhri.html, (2001), 7 pgs.
Bedell, C.,“Processing and Hydrolytic Degradation of Aromatic, Ortho-Substituted Polyanhydrides”,Journal of Applied Polymer Science, 80, (2001), pp. 32-38.
Campo, C.J., “Polyanhydrides: the effects of ring substitution changes on polymer properties”,Polymer Bulletin, 42, (1999), pp. 61-68.
Chafi, N..,“Dosage Form with Salicylic Acid Attached to the Polyanhydride Polymer Dispresed in an Eudragit Matrix”,International Journal of Pharmaceutics, 52, (1989), pp. 203-211.
Conix, A..,“Aromatic Polyanhydrides, a New Class of High Melting Fiber-Forming Polymers”,Journal of Polymer Science, XXIX, (1958),pp. 343-353.
Conix, A..,“N
Fubara Blessing
Page Thurman K.
Rutgers The State University of New Jersey
Schwegman Lundberg Woessner & Kluth P.A.
LandOfFree
Therapeutic polyesters and polyamides does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Therapeutic polyesters and polyamides, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Therapeutic polyesters and polyamides will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3345900